查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813868

藥物基因體學中的分子診斷市場規模、佔有率和趨勢分析報告：按產品、治療領域、技術、地區和細分市場預測，2025-2033 年

Molecular Diagnostics In Pharmacogenomics Market Size, Share & Trends Analysis Report By Product (Kits & Assays, Reagents, Services), By Therapeutic Area, By Technology, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

藥物基因體學中的分子診斷市場摘要

預計 2024 年全球藥物基因藥物基因體學診斷市場價值將達到 6.997 億美元，到 2033 年將達到 12.5638 億美元，2025 年至 2033 年的複合年成長率為 6.84%。

該市場專注於快速且準確的基因檢測，以實現個人化藥物治療、改善臨床結果並減少藥物不良反應。

分子診斷在識別患者特異性基因突變方面發揮核心作用，廣泛應用於腫瘤學、心血管疾病、感染疾病和神經系統疾病等領域。市場提供多樣化的產品，包括套件、試劑和專門的檢測服務，每種產品都針對藥物基因體學工作流程的不同階段。套件和試劑廣泛用於臨床實驗室和研究機構的常規和專門檢測。對全面解讀、生物資訊學支援和符合法規要求的檢測的需求正在擴大服務的相關性。在治療領域，肺癌、乳癌和大腸癌佔檢測量的大多數，人們對神經系統和免疫系統疾病的興趣也日益濃厚。

在技​​術方面，聚合酵素鏈鎖反應(PCR) 因其成本效益高、速度快，仍然是最廣泛使用的。定序技術，尤其是次世代定序(NGS)，因其能夠同時分析多個基因而日益普及。其他方法，例如微陣列、電泳和核酸擴增技術，也為檢測生態系統做出了貢獻。持續的技術創新，以及對基因-藥物交互作用認知的不斷提高，以及全球基因組服務覆蓋範圍的不斷擴大，預計將在預測期內促進該市場的成長。

此外，在2025年4月舉行的美國神經病學會（AAN）年會上，頂尖的神經科強調了藥物基因組學在神經病學領域日益重要的作用。透過關注阿茲海默症、帕金森氏症、中風、偏頭痛和多發性硬化症等疾病的遺傳因素，專家們設想了模式轉移，這可能會提高療效並減少不利事件。這些趨勢表明，神經系統護理領域對PGx分子診斷的臨床需求日益成長，這一發展反映出一種更廣泛的趨勢，即在傳統治療方法之外採用基於定序的精準診斷。

整體而言，藥物基因組學分子診斷產業的創新格局反映出人們正朝著更快速、更便利、更具臨床可操作性的檢測解決方案轉變。人工智慧、照護現場系統和多體學平台等先進技術的整合，正在將PGx診斷的效用擴展到傳統醫院環境之外，並支持其在各個治療領域的廣泛應用。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素
    • 個人化醫療需求不斷成長
    • 將基於NGS的診斷整合到臨床工作流程中
    • 擴大監管支持和報銷框架
  • 市場限制因素分析
    • 醫療專業人員和患者缺乏意識
    • 與成本相關的挑戰和報銷波動
  • 商業環境分析
    • 依因素（政治/法律、經濟、技術）進行 SWOT 分析
    • 波特五力分析
    • COVID-19影響分析

第4章 產品業務分析

  • 藥物基因體學中的分子診斷市場：產品變異分析
  • 套件和檢測試劑
    • 2021-2033年市場收益估計與預測
  • 試劑
    • 2021-2033年市場收益估計與預測
  • 服務
    • 2021-2033年市場收益估計與預測

第5章治療領域業務分析

  • 藥物基因體學中的分子診斷市場：治療領域變異分析
  • 腫瘤學
    • 2021-2033年市場收益估計與預測
    • 肺癌
    • 乳癌
    • 大腸直腸癌
    • 子宮頸癌
    • 其他
  • 神經系統疾病
    • 2021-2033年市場收益估計與預測
  • 心血管疾病
    • 2021-2033年市場收益估計與預測
  • 免疫疾病
    • 2021-2033年市場收益估計與預測
  • 感染疾病
    • 2021-2033年市場收益估計與預測
  • 其他
    • 2021-2033年市場收益估計與預測

第6章：技術業務分析

  • 藥物基因體學中的分子診斷市場：技術波動分析
  • PCR
    • 2021-2033年市場收益估計與預測
  • 微陣列
    • 2021-2033年市場收益估計與預測
  • 定序
    • 2021-2033年市場收益估計與預測
  • 其他
    • 2021-2033年市場收益估計與預測

第7章 區域業務分析

  • 2023 年及 2030 年各地區藥物基因體學分子診斷市場佔有率
  • 北美洲
    • 北美藥物基因體學（2021-2033）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲藥物基因體學
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2021-2033年亞太地區藥物基因體學體學分子診斷市場
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲藥物基因體學體學分子診斷市場（2021-2033）
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲藥物基因體學體學分子診斷市場（2021-2033）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 參與企業概況
  • 財務表現
  • 參與企業
    • 市場領導者
    • 2023年藥物基因體學學分子診斷市佔分析
    • 公司簡介
Product Code: GVR-4-68040-697-1

Molecular Diagnostics In Pharmacogenomics Market Summary

The global molecular diagnostics in pharmacogenomics market size was estimated at USD 699.7 million in 2024 and is projected to reach USD 1, 256.38 million in 2033, growing at a CAGR of 6.84% from 2025 to 2033. This market focuses on rapid and precise genetic testing that enables tailored drug therapy, improving clinical outcomes and reducing adverse drug reactions.

Molecular diagnostics play a central role in identifying patient-specific genetic variations and are widely adopted in areas such as oncology, cardiovascular conditions, infectious diseases, and neurological disorders. Product offerings within the market span across kits, reagents, and specialized testing services, each addressing different stages of pharmacogenomic workflows. Kits and reagents are widely used in clinical laboratories and research institutions for routine and specialized assays. Services are expanding in relevance due to the need for comprehensive interpretation, bioinformatics support, and regulatory-compliant testing. The oncology segment dominates the therapeutic landscape, with lung, breast, and colorectal cancers accounting for significant test volumes, while emerging interest is observed in neurological and immunological disorders.

In terms of technology, polymerase chain reaction (PCR) remains the most widely used method due to its cost-effectiveness and speed. Sequencing technologies, particularly next-generation sequencing (NGS), are gaining ground for their ability to analyze multiple genes simultaneously. Microarrays and other methods like electrophoresis and nucleic acid amplification techniques also contribute to the testing ecosystem. Continuous innovation, along with rising awareness of gene-drug interactions and expanding access to genomic services globally, is expected to reinforce the growth of this market over the forecast period.

Moreover, at AAN's Annual Meeting in April 2025, leading neurologists underscored the emergent role of pharmacogenomics in neurology. By focusing on genetic drivers across diseases like Alzheimer's, Parkinson's, stroke, migraine, and multiple sclerosis, experts envisioned a paradigm shift toward genetically guided treatment selection, with the potential to enhance efficacy and reduce adverse events. These insights point to a growing clinical demand for PGx-enabled molecular diagnostics in neurological care a development reflecting the broader trend of sequencing-based precision diagnostics being adopted beyond traditional therapeutic boundaries.

Overall, the innovation landscape in the molecular diagnostics in pharmacogenomics industry reflects a shift toward faster, more accessible, and clinically actionable testing solutions. The integration of advanced technologies such as AI, point-of-care systems, and multi-omics platforms is expanding the utility of PGx diagnostics beyond traditional hospital settings, supporting broader adoption across diverse therapeutic areas.

Global Molecular Diagnostics In Pharmacogenomics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global molecular diagnostics in pharmacogenomics market report based on the product, therapeutic area, technology, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Kits and assays
  • Reagents
  • Services
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Others
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • PCR
  • Microarray
  • Sequencing
  • Others
  • Regional Outlook (Revenue, USD Million, 2021- 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising Demand for Personalized Medicine
    • 3.4.2. Integration of NGS-Based Diagnostics in Clinical Workflows
    • 3.4.3. Expanding Regulatory Support and Reimbursement Frameworks
  • 3.5. Market Restraint Analysis
    • 3.5.1. Limited Awareness Among Healthcare Providers and Patients
    • 3.5.2. Cost-Related Challenges and Reimbursement Variability
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. Covid-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Molecular Diagnostics in Pharmacogenomics Market: Product Movement Analysis
  • 4.2. Kits and Assays
    • 4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Services
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

  • 5.1. Molecular Diagnostics in Pharmacogenomics Market: Therapeutic Area Movement Analysis
  • 5.2. Oncology
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.2. Lung Cancer
      • 5.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.3. Breast Cancer
      • 5.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.4. Colorectal Cancer
      • 5.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.5. Cervical Cancer
      • 5.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.6. Others
      • 5.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Neurological Disorders
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Cardiovascular Disease
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Immunological Disorders
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Technology Business Analysis

  • 6.1. Molecular Diagnostics in Pharmacogenomics Market: Technology Movement Analysis
  • 6.2. PCR
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Microarray
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Sequencing
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Molecular Diagnostics in Pharmacogenomics Market Share, By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Target Disease Prevalence
      • 7.2.4.3. Competitive Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Reimbursement Scenario
      • 7.2.4.6. Mexico Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. UK Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Argentina Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's Overview
  • 8.2. Financial Performance
  • 8.3. Participant Categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Molecular Diagnostics in Pharmacogenomics Market Share Analysis, 2023
    • 8.3.3. Company Profiles
      • 8.3.3.1. Roche Diagnostics
        • 8.3.3.1.1. Company Overview
        • 8.3.3.1.2. Financial Performance
        • 8.3.3.1.3. Product Benchmarking
        • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. QIAGEN
        • 8.3.3.2.1. Company Overview
        • 8.3.3.2.2. Financial Performance
        • 8.3.3.2.3. Product Benchmarking
        • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Thermo Fisher Scientific
        • 8.3.3.3.1. Company Overview
        • 8.3.3.3.2. Financial Performance
        • 8.3.3.3.3. Product Benchmarking
        • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Illumina, Inc.
        • 8.3.3.4.1. Company Overview
        • 8.3.3.4.2. Financial Performance
        • 8.3.3.4.3. Product Benchmarking
        • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. Agilent Technologies
        • 8.3.3.5.1. Company Overview
        • 8.3.3.5.2. Financial Performance
        • 8.3.3.5.3. Product Benchmarking
        • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. Abbott Molecular
        • 8.3.3.6.1. Company Overview
        • 8.3.3.6.2. Financial Performance
        • 8.3.3.6.3. Product Benchmarking
        • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Genomind
        • 8.3.3.7.1. Company Overview
        • 8.3.3.7.2. Financial Performance
        • 8.3.3.7.3. Product Benchmarking
        • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. OneOme
        • 8.3.3.8.1. Company Overview
        • 8.3.3.8.2. Financial Performance
        • 8.3.3.8.3. Product Benchmarking
        • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. Myriad Genetics
        • 8.3.3.9.1. Company Overview
        • 8.3.3.9.2. Financial Performance
        • 8.3.3.9.3. Product Benchmarking
        • 8.3.3.9.4. Strategic Initiatives
      • 8.3.3.10. Invitae (formerly YouScript)
        • 8.3.3.10.1. Company Overview
        • 8.3.3.10.2. Financial Performance
        • 8.3.3.10.3. Product Benchmarking
        • 8.3.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 Molecular Diagnostics in Pharmacogenomics Market - Industry Snapshot & Key Buying Criteria, 2021 - 2033
  • Table 2 Global Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 3 Global Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 4 Global Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 5 Global Molecular Diagnostics in Pharmacogenomics Market, by region, 2021 - 2033 (USD Million)
  • Table 6 Molecular Diagnostics in Pharmacogenomics- Key market driver analysis
  • Table 7 Molecular Diagnostics in Pharmacogenomics- Key market restraint analysis
  • Table 8 North America Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 10 North America Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 11 North America Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 12 U.S. Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 13 U.S. Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 14 U.S. Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 15 Canada Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 16 Canada Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 17 Canada Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 18 Mexico Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 19 Mexico Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 20 Mexico Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 21 Europe Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 22 Europe Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 23 Europe Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 24 Europe Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 25 Germany Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 26 Germany Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 27 Germany Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 28 UK Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 29 UK Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 30 UK Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 31 France Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 32 France Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 33 France Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 34 Italy Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 35 Italy Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 36 Italy Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 37 Spain Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 38 Spain Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 39 Spain Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 40 Denmark Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 41 Denmark Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 42 Denmark Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 43 Sweden Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 44 Sweden Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 45 Sweden Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 46 Norway Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 47 Norway Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 48 Norway Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 49 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 53 Japan Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 54 Japan Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 55 Japan Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 56 China Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 57 China Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 58 China Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 59 India Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 60 India Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 61 India Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 62 Australia Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 63 Australia Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 64 Australia Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 65 South Korea Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 66 South Korea Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 67 South Korea Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 68 Thailand Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 69 Thailand Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 70 Thailand Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 71 Latin America Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 72 Latin America Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 73 Latin America Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 74 Latin America Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 75 Brazil Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 76 Brazil Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 77 Brazil Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 78 Argentina Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 79 Argentina Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 80 Argentina Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 81 MEA Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 82 MEA Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 83 MEA Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 84 MEA Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 85 South Africa Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 86 South Africa Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 87 South Africa Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 88 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 90 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 91 UAE Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 92 UAE Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 93 UAE Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 94 Kuwait Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 96 Kuwait Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area

List of Figures

  • Fig. 1 Molecular Diagnostics in Pharmacogenomics Market Segmentation
  • Fig. 2 Global Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 3 Molecular Diagnostics in Pharmacogenomics Market Dynamics
  • Fig. 4 Key Opportunities Prioritized, 2021
  • Fig. 5 Molecular Diagnostics in Pharmacogenomics Market - Porter's Analysis
  • Fig. 6 Molecular Diagnostics in Pharmacogenomics Market - PESTEL Analysis
  • Fig. 7 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Product, 2023 & 2030
  • Fig. 8 Kits and assays Market, 2021 - 2033 (USD Million)
  • Fig. 9 Reagents Market, 2021 - 2033 (USD Million)
  • Fig. 10 Services Market, 2021 - 2033 (USD Million)
  • Fig. 11 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Technology, 2023 & 2030
  • Fig. 12 PCR Market, 2021 - 2033 (USD Million)
  • Fig. 13 Microarray Market, 2021 - 2033 (USD Million)
  • Fig. 14 Sequencing Market, 2021 - 2033 (USD Million)
  • Fig. 15 Others Market, 2021 - 2033 (USD Million)
  • Fig. 16 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Therapeutic Area, 2023 & 2030
  • Fig. 17 Oncology Market, 2021 - 2033 (USD Million)
  • Fig. 18 Lung Cancer Market, 2021 - 2033 (USD Million)
  • Fig. 19 Breast Cancer Market, 2021 - 2033 (USD Million)
  • Fig. 20 Colorectal Cancer Market, 2021 - 2033 (USD Million)
  • Fig. 21 Cervical Cancer Market, 2021 - 2033 (USD Million)
  • Fig. 22 Others Market, 2021 - 2033 (USD Million)
  • Fig. 23 Neurological Disorders Market, 2021 - 2033 (USD Million)
  • Fig. 24 Cardiovascular Disease Market, 2021 - 2033 (USD Million)
  • Fig. 25 Immunological Disorders Market, 2021 - 2033 (USD Million)
  • Fig. 26 Infectious Diseases Market, 2021 - 2033 (USD Million)
  • Fig. 27 Others Market, 2021 - 2033 (USD Million)
  • Fig. 28 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Region, 2023 & 2030
  • Fig. 29 North America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 30 US Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 32 Mexico Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 34 Germany Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 35 UK Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 36 France Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 37 Italy Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 38 Spain Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 39 Denmark Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 40 Sweden Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 41 Norway Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 42 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 43 Japan Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 44 China Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 45 India Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 46 Australia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 47 South Korea Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 48 Thailand Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 49 Latin America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 50 Brazil Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 51 Argentina Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 52 MEA Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 53 South Africa Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 54 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 55 UAE Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 56 Kuwait Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)